Skip to main content

MASH

2
Pipeline Programs
8
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Opko Health
Opko HealthMIAMI, FL
1 program
1
OPK-88006Phase 1/21 trial
Active Trials
NCT07512427Not Yet Recruiting30Est. Dec 2027
Genentech
GenentechCA - Oceanside
1 program
1
RO7790121Phase 11 trial
Active Trials
NCT06903065Active Not Recruiting50Est. Dec 2026
Innovation Pharmaceuticals
1 program
Global Research Initiative for Patients Screening on MASHN/A1 trial
Active Trials
NCT05651724Recruiting10,000Est. Mar 2031
Inventiva
InventivaDAIX, France
1 program
Global Research Initiative for Patients Screening on MASHN/A
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
Global Research Initiative for Patients Screening on MASHN/A
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Global Research Initiative for Patients Screening on MASHN/A
Echosens
EchosensFrance - Paris
1 program
Global Research Initiative for Patients Screening on MASHN/A
Sagimet Biosciences
Sagimet BiosciencesCA - San Mateo
1 program
DenifanstatPHASE_3Small Molecule1 trial
Active Trials
NCT06594523Withdrawn0Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
Sagimet BiosciencesDenifanstat
Opko HealthOPK-88006
GenentechRO7790121
Innovation PharmaceuticalsGlobal Research Initiative for Patients Screening on MASH

Clinical Trials (4)

Total enrollment: 10,080 patients across 4 trials

NCT06594523Sagimet BiosciencesDenifanstat

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Start: Mar 2025Est. completion: Dec 20300
Phase 3Withdrawn
NCT07512427Opko HealthOPK-88006

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

Start: Dec 2026Est. completion: Dec 202730 patients
Phase 1/2Not Yet Recruiting
NCT06903065GenentechRO7790121

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Start: Apr 2025Est. completion: Dec 202650 patients
Phase 1Active Not Recruiting
NCT05651724Innovation PharmaceuticalsGlobal Research Initiative for Patients Screening on MASH

Global Research Initiative for Patients Screening on MASH

Start: Jun 2023Est. completion: Mar 203110,000 patients
N/ARecruiting

Related Jobs

Postdoctoral Scientist – Fibrosis, Liver Disease

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite Required)
1w ago
$127K - $164K/yr

Director, Marketing Operations

Madrigal PharmaceuticalsMadrigal Pharmaceuticals
Conshohocken - Office, PA
2w ago
$214K - $261K/yr

Area Business Manager - Central Alabama

Madrigal PharmaceuticalsMadrigal Pharmaceuticals
Alabama - Field, AL
2w ago
$158K - $193K/yr

Grants Manager

Madrigal PharmaceuticalsMadrigal Pharmaceuticals
Remote
3w ago
$139K - $170K/yr

Quality Compliance Lead International

Madrigal PharmaceuticalsMadrigal Pharmaceuticals
Zug - Switzerland - Office
3w ago

Quality Assurance Lead - FvP

Madrigal PharmaceuticalsMadrigal Pharmaceuticals
Zug - Switzerland - Office
3w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 10,080 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.